TipHub

₹14.9

▲ +0.47 +3.26%

As of 27 Jul 2026 · delayed

NSE Listed

GSM · GSM 0
What does GSM · GSM 0 mean?
BSE · Graded Surveillance Measure (GSM 0)GSM targets fundamentally weak companies whose price doesn't square with their financials (tiny net worth or negative/extreme P/E). Practical meaning: the exchange doubts the price is backed by the business. Stage 0 is a watchlist; each higher stage makes the stock progressively harder to trade — tighter bands, full upfront margin, weekly-only trading, and at Stage IV no upward price movement at all. Exiting requires a quarterly review finding the criteria no longer met.Criteria: Shortlisted on objective financial parameters — net worth, net fixed assets, price-to-earnings multiple and market capitalisation. Stage 0 = base surveillance watchlist (identified under GSM, no graded price restriction yet); Stages I–VI add escalating curbs (price band, 100% margin, periodic call auction, settlement on a gross/trade-for-trade basis, no upward price movement).
NSE · Graded Surveillance Measure (GSM 0)GSM targets fundamentally weak companies whose price doesn't square with their financials (tiny net worth or negative/extreme P/E). Practical meaning: the exchange doubts the price is backed by the business. Stage 0 is a watchlist; each higher stage makes the stock progressively harder to trade — tighter bands, full upfront margin, weekly-only trading, and at Stage IV no upward price movement at all. Exiting requires a quarterly review finding the criteria no longer met.Criteria: Shortlisted on objective financial parameters — net worth, net fixed assets, price-to-earnings multiple and market capitalisation. Stage 0 = base surveillance watchlist (identified under GSM, no graded price restriction yet); Stages I–VI add escalating curbs (price band, 100% margin, periodic call auction, settlement on a gross/trade-for-trade basis, no upward price movement).Exchange notice

Ortin Global Ltd (ORTINGLOBE)

Volume: 6,735Avg Vol 1W: 4,506.6Avg Vol 1M: 23,497.5552W Range:₹10.66₹21.3
NSE AI Report
Key Ratios
Checked 2d ago
Market Cap₹14 Cr
Current Price₹14.9
Previous Close₹14.43
High / Low (52w)₹21.3 / ₹10.66
Volume6,735
Avg Vol (1W)4,506.6
Avg Vol (1M)23,497.55
Stock P/E—
Book Value₹1.33
Dividend Yield—
ROE-46.1%
ROA-15.4%
Revenue (TTM)—
Revenue Growth-24.1%
Profit Margin0%
Total Debt₹1 Cr
Shares Outstanding1 Cr
Face Value—
EPS (TTM)₹-0.91
P/B12.85
Debt / Equity81.24
50 DMA₹16.61
200 DMA₹14.75
Day change+3.26%
SurveillanceGSM · GSM 0
Price Chart
₹14.9▲ 5.23% · 1Y
₹20₹114.5L
2025-07-30
2026-07-27

20-day avg volume: 23K shares

Quarterly Results
MetricJun 2011Mar 2012Jun 2012Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹20 Cr₹20 Cr₹16 Cr₹4,53,000 Cr₹3,98,000 Cr₹1,40,000 Cr₹1,23,000 Cr₹3,44,000 Cr
EBITDA₹2 Cr₹-1 Cr₹2 Cr₹-16,10,000 Cr₹-16,25,000 Cr₹-50,15,000 Cr₹-4,95,000 Cr₹-77,000 Cr
Net Profit₹1 Cr₹-2 Cr₹0 Cr₹-16,41,000 Cr₹-17,54,000 Cr₹-50,25,000 Cr₹-5,32,000 Cr₹-93,000 Cr
EPS———-0.2-0.22-0.62-0.07-0.01
Profit & Loss (Annual)
MetricSept 2024Dec 2024Mar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
EBITDA₹0 Cr₹0 Cr₹-1 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Net Profit₹0 Cr₹0 Cr₹-1 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
EPS——-1.04—————
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹105 Cr₹117 Cr₹21 Cr₹21 Cr₹21 Cr₹7 Cr₹4 Cr₹5 Cr
Total Liabilities₹80 Cr₹93 Cr₹10 Cr₹10 Cr₹10 Cr₹4 Cr₹2 Cr₹3 Cr
Equity₹25 Cr₹24 Cr₹11 Cr₹11 Cr₹11 Cr₹3 Cr₹2 Cr₹1 Cr
Total Debt———————₹1 Cr
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹18 Cr₹2 Cr₹0 Cr₹-3 Cr₹0 Cr₹-55,96,000 Cr
Investing₹0 Cr₹0 Cr₹0 Cr₹12 Cr₹0 Cr₹3,90,000 Cr
Financing₹-10 Cr₹0 Cr₹1 Cr₹-3 Cr₹0 Cr₹75,28,000 Cr
Free Cash Flow₹18 Cr₹2 Cr₹0 Cr₹-3 Cr₹0 Cr₹-55,96,000 Cr
Shareholding
Promoter 1.23% Institutions 1.8% Public 96.96%
About Ortin Global Ltd

Healthcare · Drug Manufacturers - Specialty & Generic

Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders; formulations, such as anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides. Its formulations also include chemo therapeutics, antacids and anti-ulcerants, anti-spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti-retroviral products. In addition, the company offers active pharmaceutical ingredient (API) intermediates, including anti-retroviral, anti-diabetics, analgesics and antipyretics, anti-biotics, antifungal, antacids and anti-ulcerants, and anti-malarials; and manufactures fine chemicals, and grignard and alkali metal products. Further, the company provides services in the areas of process development, process and product characterization, analytical research and development, and assay development; research and development services for new formulation brands; and diagnostic services comprising development of rapid flow kits, assays, and reagents. Additionally, it undertakes long-term contracts for manufacturing intermediates and developing new APIs; operates as a merchant exporter of pharmaceutical finished formulations; and engages in real estate. The company was formerly known as Ortin Laboratories Limited and changed its name to Ortin Global Limited in June 2024. Ortin Global Limited was incorporated in 1986 and is headquartered in Hyderabad, India.

Efficiency & Working Capital
ROCE0%
Interest Coverage0
Dividend Payout—
Debtor Days279 d
Inventory Days21 d
Payable Days45 d
Cash Conversion Cycle255 d
Working Capital Days300 d
Shareholding Details

As of 2026-06-30

Promoter1.2%
FII1.8%
DII0%
Institutions1.8%
Public97%
Promoter Pledge0%
No. of Shareholders11,383
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters7.4%7.4%1.2%1.2%1.2%1.2%1.2%1.2%1.2%1.2%1.2%1.2%
FIIs0%0%0%6.2%6.2%6.2%6.5%6.5%1.7%1.7%1.7%1.8%
DIIs0%0%0%0%0%0%0%0%0%0%0%0%
Public92.6%92.6%98.8%92.5%92.5%92.5%92.2%92.2%97.1%97.1%97.1%97%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders11,83612,31412,19211,95212,16512,09412,14412,03412,06011,83411,45211,383
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503————
Major Shareholders (>1%)
NameCategoryStakeShares
Suresh GadalayPublic Shareholding6.4%5,16,205
Rajesh PoddarPublic Shareholding4.7%3,81,467
Mir Ata Ali KhanPublic Shareholding2.7%2,15,231
Nallavolu JayammaPublic Shareholding1.7%1,37,210
Wave Capital LtdPublic Shareholding1.7%1,36,676
Prabha Rameshkumar GuptaPublic Shareholding1.1%91,420
Saadvik Raghuram YellareddygariPublic Shareholding1.1%85,000
Sanka Tandav KrishnaShareholding of Promoter and Promoter Group0.5%40,512
Venkata Sujatha SankaShareholding of Promoter and Promoter Group0.3%21,944
Lakshmi Sravani DasariShareholding of Promoter and Promoter Group0.3%20,000
Murali Krishna Murthy SankaShareholding of Promoter and Promoter Group0.2%17,844
Balaji Venkateswarlu SankaShareholding of Promoter and Promoter Group0%0
Sanka Sharath KumarShareholding of Promoter and Promoter Group0%0
Venkata Ratnamma SankaShareholding of Promoter and Promoter Group0%0
Srinivasa Kumar SankaShareholding of Promoter and Promoter Group0%0
Sanka Hema KumariShareholding of Promoter and Promoter Group0%0
Venkata Subbamma SankaShareholding of Promoter and Promoter Group0%0
Sanka Ravi SankarShareholding of Promoter and Promoter Group0%0
Sanka Satya Praveen KumarShareholding of Promoter and Promoter Group0%0
Sanka Naga JyothiShareholding of Promoter and Promoter Group0%0
Krishna Karthik SankaShareholding of Promoter and Promoter Group0%0
Board of Directors
NameDesignationYear
S Murali Krishna MurthyManaging Director2025
Pramod Dnyandeo Wag HeNon Executive Director2025
Mounika PammiIndependent Director2025
Prashant Prakash SawantWhole-time Director2025
Prakruti Prakash SawantWhole-time Director2025
Sarang Balbhimrao PatodekarChairman & Independent Directo2025
Ajay VishwakarmaIndependent Director2025
Madhu SolankiCompany Sec. & Compli. Officer2025
Segments — Product
SegmentRevenueShare
Manufacture of Pharmaceutical Produ₹0 Cr—
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹101088
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2025000102
2025000102
2025000000
Insider / Designated-Person Trades

28 recent disclosure(s)

Sanka Satya Praveen KumarDisposal · 78,071
Sanka Venkata SubbammaDisposal · 27,216
Sanka Srinivas KumarDisposal · 1,27,175
Lakshmi Sravani DasariDisposal · 32,000
Sanka Sarath KumarDisposal · 32,696
Sanka Venkata RatnammaDisposal · 42,346
Substantial Acquisitions (SAST)

1 disclosure(s)

Market23/02/2026 · 31,640
Company Information
Incorporated1986
ChairmanSarang Balbhimrao Patodekar
AuditorMathesh & Ramana
Investor Email[email protected]
🌐 www.ortinlabsindia.com ↗

📍 D No 1-8-B4 Ground Floor F3, HIG Block-4 Street No 3, Hyderabad, Telangana, 500044

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Orient Press LimitedOrient Paper & Industries Ltd.Orient Technologies Ltd.Orissa Minerals Development Company Ltd.Orkla India LimitedOrtel Communications Ltd.Oriental Infra TrustOsel Devices LimitedOsia Hyper Retail LimitedOswal Agro Mills Ltd.Oswal Greentech LimitedOswal Pumps LimitedAll “O” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search